Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + methotrexate + cytarabine + cyclophosphamide + ifosfamide + vincristine + vindesine + temozolomide + liposomal cytarabine
- Development stage
- Unknown
- Lead developer
- Aarhus University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intrathecal, Oral
01
Overview
This multi-agent immunochemotherapy regimen was developed and studied by the **University of Aarhus** for the treatment of newly diagnosed **primary central nervous system lymphoma (PCNSL)**. The intensive induction phase combines the anti-CD20 monoclonal antibody **rituximab** with several cytotoxic agents: high-dose methotrexate (HD-MTX), high-dose cytarabine (HD-Ara C), cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide, and intrathecal liposomal cytarabine (DepoCyte). This regimen is specifically designed to penetrate the blood-brain barrier and provide comprehensive coverage against CNS lymphoma cells without the use of whole-brain radiotherapy, thereby aiming to reduce long-term neurotoxicity while maintaining therapeutic efficacy. In elderly patients, the induction phase is followed by maintenance treatment with temozolomide.
- Other names
- Aarhus PCNSL regimenAarhus protocolImmunochemotherapy
02
Targets
MRP2 (Canalicular multispecific organic anion transporter 1)CD20 (B-lymphocyte antigen CD20)MRP3 (Multidrug resistance-associated protein 3)DNAABCC4 (Multidrug resistance-associated protein 4)ABCB11 (Bile salt export pump)
Beyond the preview
Go deeper on rituximab + methotrexate + cytarabine + cyclophosphamide + ifosfamide + vincristine + vindesine + temozolomide + liposomal cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + methotrexate + cytarabine + cyclophosphamide + ifosfamide + vincristine + vindesine + temozolomide + liposomal cytarabine.